On Nov 19, major Wall Street analysts update their ratings for $Aclaris Therapeutics (ACRS.US)$, with price targets ranging from $3 to $13.
Jefferies analyst Roger Song upgrades to a buy rating, and adjusts the target price from $1 to $7.
Stifel analyst Alex Thompson CFA maintains with a hold rating, and maintains the target price at $3.
BTIG analyst Julian Harrison upgrades to a buy rating, and sets the target price at $8.
Piper Sandler analyst Christopher Raymond upgrades to a buy rating, and adjusts the target price from $2 to $13.
Leerink Partners analyst Thomas Smith upgrades to a buy rating, and adjusts the target price from $2 to $7.
Furthermore, according to the comprehensive report, the opinions of $Aclaris Therapeutics (ACRS.US)$'s main analysts recently are as follows:
BSI-045B, being the first anti-TSLP demonstrating clinical proof of concept in atopic dermatitis, is considered to be underpinned by a distinct binding profile. Further development in a placebo-controlled study is supported for additional substantiation in atopic dermatitis and potentially other areas. Should these studies prove successful, BSI-045B could emerge as a pioneer in the congested atopic dermatitis market with a unique mechanism of action that potentially improves both efficacy and safety.
Aclaris Therapeutics has taken a significant step by acquiring the complete ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb. This acquisition is highlighted by the remarkable potency of BSI-045B, which has demonstrated up to 71-times greater efficacy versus tezepelumab, and up to nine times higher potency compared to other anti-TSLP therapies currently under development. Impressively, early Phase 2a open-label data suggests that BSI-045B could become a preferred early-line treatment for atopic dermatitis.
Here are the latest investment ratings and price targets for $Aclaris Therapeutics (ACRS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
